PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance

PURPOSE: To investigate the clinical relevance of PTEN in HER2-amplified and HER2-non-amplified disease. EXPERIMENTAL DESIGN: We assessed PTEN status in two large adjuvant breast cancer trials (BCIRG-006 and BCIRG-005) using a PTEN IHC assay that was previously validated in a panel of 33 breast canc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Stern, Howard M., Gardner, Humphrey, Burzykowski, Tomasz, Elatre, Wafaa, O’Brien, Carol, Lackner, Mark R., Pestano, Gary A., Santiago, Angela, Villalobos, Ivonne, Eiermann, Wolfgang, Pienkowski, Tadeusz, Martin, Miguel, Robert, Nicholas, Crown, John, Nuciforo, Paolo, Bee, Valerie, Mackey, John, Slamon, Dennis J., Press, Michael F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4417419/
https://ncbi.nlm.nih.gov/pubmed/25649019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2993
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados